Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study

Published:2023-05-26 Issue:5 Volume:24 Page:837-847
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

Terui Tadashi^ORCID,Okubo Yukari^ORCID,Kobayashi Satomi,Sano Shigetoshi,Morita Akimichi^ORCID,Imafuku Shinichi,Tada Yayoi^ORCID,Abe Masatoshi,Yaguchi Masafumi,Uehara Natsuka,Handa Takahiro,Tanaka Masayuki,Zhang Wendy,Paris Maria,Murakami Masamoto

Funder

Amgen

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40257-023-00788-2.pdf

Reference51 articles.

1. Murakami M, Terui T. Palmoplantar pustulosis: current understanding of disease definition and pathomechanism. J Dermatol Sci. 2020;98(1):13–9.

2. Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2020;21(3):355–70.

3. Masuda-Kuroki K, Murakami M, Kishibe M, Kobayashi S, Okubo Y, Yamamoto T, et al. Diagnostic histopathological features distinguishing palmoplantar pustulosis from pompholyx. J Dermatol. 2019;46(5):399–408.